Article Information
History
- November 16, 2021.
Article Versions
- You are currently viewing Version 1 of this article (November 16, 2021 - 07:13).
- Version 2 (December 9, 2021 - 09:31).
- View Version 3, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Flonza Isa1,*,
- Eduardo Forleo-Neto1,
- Jonathan Meyer1,
- Wenjun Zheng1,
- Scott Rasmussen2,
- Danielle Armas3,
- Masaru Oshita4,
- Cynthia Brinson5,
- Steven Folkerth6,
- Lori Faria1,
- Ingeborg Heirman1,
- Neena Sarkar1,
- Bret J. Musser1,
- Shikha Bansal1,
- Meagan P. O’Brien1,
- Kenneth C. Turner1,
- Samit Ganguly1,
- Adnan Mahmood1,
- Ajla Dupljak1,
- Andrea T. Hooper1,
- Jennifer D. Hamilton1,
- Yunji Kim1,
- Bari Kowal1,
- Yuhwen Soo1,
- Gregory P. Geba1,
- Leah Lipsich1,
- Ned Braunstein1,
- George D. Yancopoulos1,
- David M. Weinreich1,
- Gary A. Herman1 and
- the COVID-19 Multi-dose Trial Team
- 1Regeneron Pharmaceuticals, Inc., Tarrytown, NY
- 2Celerion, Lincoln, NE
- 3Celerion, Tempe, AZ
- 4Benchmark Research, Sacramento, CA
- 5Central Texas Clinical Research, LLC, Austin, TX
- 6Midwest Clinical Research Center, LLC, Dayton, OH
- ↵*Correspondence to:
Flonza Isa, MD; Email: flonza.isa{at}regeneron.com